Novaliq Names Renown International Experts to Inaugural Scientific Advisory Board
Novaliq GmbH, a pharmaceutical company with a disruptive drug delivery platform to transform poorly soluble drugs into effective therapeutics for ophthalmology, announced today the appointment of several renown experts to its newly formed scientific advisory board (SAB). The newly appointed SAB will strategically advise and support Novaliq as it continues to develop and bring to market innovative therapies for a broad range of ophthalmic indications, including dry eye and glaucoma.
The initial members of the Novaliq SAB include:
- Claus Cursiefen, M.D., Ph.D., FEBO, chairman and professor, Department of Ophthalmology, University of Cologne, Germany. Prof. Cursiefen’s expertise lies in corneal lymphangiogenesis and cellular immunity in inflammatory eye diseases; corneal transplantation and ocular surface reconstruction; and, dry eye disease. A board member of DFG Neuroscience (“Fachkollegium”) and of the Cornea Section of the German Ophthalmological Society (DOG), Prof. Cursiefen is an internationally recognized speaker and has authored or co-authored more than 300 scientific publications. Prof. Cursiefen is a member of prestigious Leopoldina and Speaker of the only DFG Research Unit in Ophthalmology (www.for2240.de).
- Norbert Pfeiffer, M.D., Ph.D., chairman and director, Department of Ophthalmology, The University Hospital Mainz, Germany. Prof. Pfeiffer’s research has focused on elucidating important aspects of the diagnosis and treatment of glaucomatous disease combining both morphological and functional aspects, and introducing basic science methods into the clinical diagnosis and treatment of glaucoma. A member of several national and international societies, including the American Academy of Ophthalmology (AAO), the Association for Research in Vision and Ophthalmology (ARVO), and the prestigious Leopoldina, Prof. Pfeiffer has authored or co-authored more than 400 scientific presentations and was awarded several scientific prizes including the Galenus von Pergamon prize.
- Michael E. Stern, Ph.D., chief scientific officer, ImmunEyez, LLC, Orange County, California. Formerly the principal scientist as well as the vice president of Inflammation Research Program at Allergan where he worked for more than 26 years, Dr. Stern’s focus has been on identifying novel mechanisms and drug targets for immune-based inflammatory diseases that affect the ocular surface. His research has been instrumental to understanding the immunopathogenesis of ocular inflammatory disease and has led to the identification of target specific therapeutics, including RESTASIS®, the first FDA approved therapy for the treatment of dry eye disease. Dr. Stern has authored or co-authored more than 300 scientific publications and abstracts, is on the editorial board of The Ocular Surface, Journal of Ocular Pharmacology and Therapeutics, and Investigative Ophthalmology and Visual Science. He has received many honors, including the Diaz Caneja Award and the International Ocular Surface Society Award.
- Kazuo Tsubota, M.D., chairman and professor of Ophthalmology, Keio University School of Medicine, Tokyo, Japan and co-director of Health Science Laboratory, Keio University-Shonan Fujisawa Campus, Kanagawa, Japan. An expert in tear film and ocular surface disease, Prof. Tsubota is a member of several national and international societies, including AAO, ARVO, and the American Academy of Cataract & Refractive Surgery (ASCRS), TFOS, and is a founding and board member of Sjogren’s Syndrome Association and Dry Eye Research Group, both in Japan. Prof. Tsubota serves on several editorial boards, has received awards from several ophthalmic societies, and has authored or co-authored more than 700 scientific publications.
"We are pleased and honored to have four distinguished experts in cornea, dry eye and glaucoma joining Novaliq’s team of advisors,” said Bernhard Günther, managing director and CEO of Novaliq GmbH. “I am confident that their experience and background will prove to be invaluable as we move our dry eye and glaucoma drug candidates through clinical development and trials.”
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq’s most advanced product is NovaTears® with CE-marking based on Novaliq’s proprietary EyeSol technology. NovaTears is marketed under the brand name EvoTears® in Europe. More on www.novaliq.com.
Bernhard Günther, + 49 6221 502 5911
Managing Director, CEO
Oliver Schlüter, PhD, + 49 6221 502 59155
Managing Director, CFO
Scotia Vision Consultants
Michael O’Rourke, + 1-813-323-1438
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AURAK Enters into a Memorandum of Understanding with Al-Farabi Kazakh National University22.7.2018 09:52 | Pressemelding
The American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, and the Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan, signed a Memorandum of Understanding (MoU), agreeing to exchange students, faculty, and research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180722005025/en/ The Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan and the American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, exchange a gift to commemorate their universities uniting in an MoU agreement. (Photo: AETOSWire) In the spirit of fostering a close international relationship between the Republic of Kazakhstan and the United Arab Emirates, developing bilateral relations in educational and scientific fields, and wishing to make their own contributions to the
Philip Morris International Announces Non-Executive Board Chairman Louis Camilleri to Assume CEO Role at Ferrari S.p.A.21.7.2018 18:19 | Pressemelding
The board of directors of Philip Morris International (NYSE:PM) has its board member, Sergio Marchionne, and his family in our thoughts and prayers during this challenging time. We congratulate our board chairman, Louis Camilleri, as he assumes the role of CEO of Ferrari S.p.A. The long term relationship between our two companies is deep and meaningful and we look forward to continued business collaboration. Mr. Camilleri will continue to serve as non-executive chairman of the PMI board. Philip Morris International: Who We Are We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirem
Loxam Announces a Conditional Agreement to Acquire UK Platforms20.7.2018 14:51 | Pressemelding
Loxam Group (“Loxam”) announces that its wholly-owned subsidiary Nationwide Platforms Limited (“Nationwide”) has entered into a conditional agreement with HSS Hire Group plc (“HSS”) with respect to the acquisition of UK Platforms Limited (“UKP”). UKP specializes in renting powered access equipment from its 12 branches located throughout the United Kingdom. The company has approximately 130 employees and operates a fleet of 3,000 units. UKP is controlled by HSS since 2013. As part of this transaction, Nationwide has entered into a commercial agreement with HSS to provide powered access equipment to complement HSS’ existing fleet. The closing of the transaction is subject to the approval by HSS’ shareholders and the confirmation that it will not be referred to the Competition and Mergers Authority. The transaction is expected to close before year end 2018. Don Kenny, CEO of Loxam’s Powered Access Division states: “I am delighted with the acquisition of UKP which will further reinforce NW
Schlumberger Announces Second-Quarter 2018 Results20.7.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2018 Mar. 31, 2018 Jun. 30, 2017 Sequential Year-on-year Revenue $8,303 $7,829 $7,462 6% 11% Pretax operating income $1,094 $974 $950 12% 15% Pretax operating margin 13.2% 12.4% 12.7% 75 bps 45 bps Net income - GAAP basis $430 $525 $(74) -18% n/m Net income, excluding charges & credits* $594 $525 $488 13% 22% Diluted EPS - GAAP basis $0.31 $0.38 $(0.05) -18% n/m Diluted EPS, excluding charges & credits* $0.43 $0.38 $0.35 13% 23% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “The second quarter was both busy and exciting for Schlumberger as we completed a number of major milestones in preparation for the broad-based global activity upturn that is now emerging. We delivered solid top-line gro
H.I.G. Capital Announces the Sale of KidsFoundation19.7.2018 19:50 | Pressemelding
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €21 billion of equity capital under management, announced today that one of its affiliates has entered a definitive agreement to sell the KidsFoundation Group (“KidsFoundation”), the Dutch market leader in childcare services, to Onex Corporation (“Onex”)(TSX:ONEX). Terms were not disclosed. Headquartered in Almere, the Netherlands, KidsFoundation provides high-quality childcare to nearly 30,000 children between the ages of six weeks and 12 years. H.I.G. created KidsFoundation in 2014 through the acquisition of assets from the estate of Estro Group. During H.I.G.’s ownership, the company has developed strongly with significant capital invested by H.I.G. to create a high-quality childcare offering. H.I.G. worked with KidsFoundation management to optimise the footprint of the company by exiting loss-making locations, introduce new IT systems to drive operational improvement and develop an internal M&
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results19.7.2018 16:01 | Pressemelding
We are pleased to announce our quarterly conference call to discuss the results of SIG Combibloc Group Holdings S.à r.l. for the second quarter ended June 30, 2018. Date: Monday, July 23, 2018 Time: 15.00 CEST / 14.00 BST / 9.00 EDT The call information will be distributed on our secure site. If you would like access to our call, please contact firstname.lastname@example.org . Regards, SIG Combibloc Group Holdings S.à r.l. View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005634/en/ Contact information SIG Combibloc Group Holdings S.à r.l. Jennifer Gough email@example.com